- Home
- GLTO vs SNES Comparison
GLTO vs SNES Comparison
Compare GLTO & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- SNES
- Stock Information
- Founded
- GLTO 2011
- SNES 2004
- Country
- GLTO Denmark
- SNES United States
- Employees
- GLTO N/A
- SNES N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- SNES Agricultural Chemicals
- Sector
- GLTO Health Care
- SNES Industrials
- Exchange
- GLTO Nasdaq
- SNES Nasdaq
- Market Cap
- GLTO 23.7M
- SNES 24.0M
- IPO Year
- GLTO 2020
- SNES 2016
- Fundamental
- Price
- GLTO $10.99
- SNES $3.80
- Analyst Decision
- GLTO Buy
- SNES Strong Buy
- Analyst Count
- GLTO 1
- SNES 1
- Target Price
- GLTO $10.00
- SNES $10.00
- AVG Volume (30 Days)
- GLTO 7.6M
- SNES 112.0K
- Earning Date
- GLTO 10-31-2025
- SNES 11-11-2025
- Dividend Yield
- GLTO N/A
- SNES N/A
- EPS Growth
- GLTO N/A
- SNES N/A
- EPS
- GLTO N/A
- SNES N/A
- Revenue
- GLTO N/A
- SNES $2,093,000.00
- Revenue This Year
- GLTO N/A
- SNES $49.17
- Revenue Next Year
- GLTO N/A
- SNES $89.89
- P/E Ratio
- GLTO N/A
- SNES N/A
- Revenue Growth
- GLTO N/A
- SNES 36.89
- 52 Week Low
- GLTO $2.01
- SNES $1.30
- 52 Week High
- GLTO $31.70
- SNES $6.24
- Technical
- Relative Strength Index (RSI)
- GLTO 58.62
- SNES 39.63
- Support Level
- GLTO $10.53
- SNES $3.86
- Resistance Level
- GLTO $18.45
- SNES $4.19
- Average True Range (ATR)
- GLTO 2.35
- SNES 0.34
- MACD
- GLTO 0.43
- SNES -0.03
- Stochastic Oscillator
- GLTO 26.56
- SNES 6.59
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.